Two children with relapsed and refractory pre–B-cell ALL received infusions of T cells transduced with anti-CD19 antibody and a T-cell signaling molecule (CTL019 chimeric antigen receptor T ...

Chimeric antigen receptor T cell (CAR-T) therapy has transformed treatment options for many cancer patients. CAR-T infusion products are made by taking the patient’s own T cells, transferring the CAR ...

Genetic engineering technologies allow for the creation of custom-made cells that can have transformative effects on human health. This is best exemplified by chimeric antigen receptor (CAR ...

A group of researchers at Children's Hospital of Philadelphia (CHOP), in collaboration with Beam Therapeutics, have tested and developed an "off-the-shelf" chimeric antigen receptor T-cell (CART ...

A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...

including T-cells; if the cancer antigen is a target of CAR-Ts, this results in CAR-Ts killing each other or fratricide. The addition of intracellular domain of CTLA-4 prevented trogocytosis and ...

(MEMPHIS, Tenn. – November 30, 2023) Immunotherapy using modified chimeric antigen receptor (CAR) T cells has greatly improved survival rates for pediatric patients with relapsed and recurrent ...

We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta ...